Pharma Deals Review, Vol 2008, No 96 (2008)

Font Size:  Small  Medium  Large

Antisoma's Shares Rise as Company Announces Acquisition of Xanthus

The PharmaDeals Team

Abstract


UK cancer biotech Antisoma is to acquire private US company Xanthus Pharmaceuticals, which develops small molecule cancer and autoimmune disorder therapeutics. The all-share deal values Xanthus at £26.8 million ($52.2 million).

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.